Technical Feasibility and Design of a Shape Memory Alloy Support Device to Increase Ejection Fraction in Patients with Heart Failure
- 337 Downloads
Heart failure is increasingly prevalent in the elderly. Treatment of patients with heart failure aims at improving their clinical condition, quality of life, prevent hospital (re)admissions and reduce mortality. Unfortunately, only a select group of heart failure patients with reduced ejection fraction are eligible for Cardiac Resynchronization Therapy where 30–40% remain non-responders and need left ventricular support. The aim of this study is to investigate if a shape memory alloy (SMA) is able to increase the ejection fraction of a mono-chamber static heart model by 5%.
A pediatric ventilation balloon was used as a heart model (mono-chamber). Flexinol®, a SMA, was placed around the heart model in multiple configurations and activated using pulse width modulation techniques to determine influence of diameter and configuration on volume displacement. Furthermore, pressure within the heart model was measured with a custom-made pressure sensor.
SMA with a diameter of 0.38 mm, placed in a spiral shape and activated with a duty cycle of 80% and a frequency of 50/min gave the highest ejection fraction increase of 3.5%.
This study demonstrated the feasibility of volume displacement in a static heart model by activation of SMA-wires. Configuration, duty cycle, frequency, pulse intervals and diameter were identified as important factors affecting the activation of SMA-wires on volume displacement. Future research should include the use of parallel SMA-wires, prototype testing in dynamic or ex vivo bench models.
KeywordsShape memory alloy Heart failure Ejection fraction Cardiac support device Design configuration
Epidemiology and Current Practice
Heart failure (HF) is characterized by the “inability of the heart to pump blood at an adequate volume”26 and results in marked limitation of physical activity. Over 6.5 million Americans have HF and increases by 46% in 2030.3 HF is an incurable, lethal disease, where 1 in 8 deaths are related to HF with a 5-year mortality rate after diagnosis of HF of 50%.8 Also, HF is the most expensive diagnosis for hospitalizations and 30-day readmissions.6
Treatment of heart failure focuses on quality of life improvement, prevention of hospital admissions and aim to decrease mortality. For patients with a reduced left ventricular ejection fraction (HFrEF) below 40%, pharmacological treatment with angiotensin-converting enzyme inhibitors, beta-blockers and mineralocorticoid/aldosterone receptor antagonists improve survival rates.19 To reduce the risk of sudden death, implantation of an Implantable Cardioverter Defibrillator is recommended. For symptomatic patients, Cardiac Resynchronization Therapy (CRT) is indicated for a select group of patients, yet over 30% of patients are non-responders and do not benefit from this treatment.2 For patients with resistant symptoms, surgical implantation of a Left Ventricular Assist Device (LVAD) or heart transplantation may be considered,19 despite drawbacks of infection of the external battery driveline occurring up to 35%14,16 and an increased risk for thrombogenicity and thrombosis.1
Shape Memory Alloys (SMAs) are able to recover their shape after unloading from a particular stimulus, such as temperature.9 At high temperature, these SMAs contract and reverts to its original state during the cooling process.11 Application of SMAs in medical practice, such as coronary stents, has continued to emerge since its discovery in the early 1930s.17 SMAs have effective strain generation up to 4%, with fatigue between 4 and 8%, high strength to weight ratio, and low operating voltage.15,20 Recently, the use of SMAs in the treatment of heart failure in bench models generated considerable attention.12,23 A mechano-electric artificial myocardial assist system using SMA-wires augmented aortic flow rate by 15% in a goat study. Also, systolic left ventricular pressure was elevated by 7% under the cardiac output condition of 3L/min in these goats.21
However, challenges remain with respect to energy supply, relaxation times of SMAs and testing in realistic heart models.
In this demonstrator study, we investigate which SMA designs, and which Pulse Width Modification (PWM) techniques are able to increase ejection fraction of a mono-chamber static heart model by at least 5%.
Materials and Methods
Images were recorded with a compact camera, processed by dedicated software using Kinovea 0.8.15 (France) where volume level was tracked as a function of time for all design configurations. Displaced volumes and corresponding ejection fractions were calculated using Microsoft Excel 2016. Graphs were made with GraphPad Prism 5 (GraphPad Software, Inc., San Diego, CA, U.S.A.).
PWM techniques were used (Fig. 1) to alter pulse frequency (50–90/min), duty cycle (20–80%) and pulse intervals (1–5) to elicit maximal volume displacement of a single SMA-wire.
GraphPad Prism 5 was used to perform statistical analysis. Results were considered statistically significant at the 5% level. A one-way ANOVA and a Tukey post hoc test was used for experiments with different SMA configurations and activation frequencies. A repeated measures ANOVA with a Tukey post hoc test was used for experiments with different pulse intervals. Results are reported as mean ± SD. Error bars represent 95% Confidence Interval.
Pulse Width Modulation (PWM) Techniques
Furthermore, volume displacement reached a constant volume after 3 pulses, regardless of the employed pulse frequency. A Tukey post hoc test revealed a significantly higher volume displacement for a frequency of 50/min (1.6 mL ± 0.04, p < 0.05) as compared to other frequencies. Both higher duty cycles and higher electric currents increased volume displacement and flow (Figs. 8b and 8c). A duty cycle of 90 or 100% would impair the cooling process and was not tested.
In this study we investigated optimal design characteristics of a demonstrator SMA support device for HFrEF patients. A 380 µm SMA Flexinol® wire configured in a spiral oriented shape around a mono-chamber balloon activated with a duty cycle of 80%, a frequency of 50/min gave the highest volume displacement (stroke volume, 6.2 mL). A maximum ejection fraction (EF) of 3.5% was achieved, requiring a power supply of 25 V and 2.85 A for each pulse.
Tozzi et al. used a 100 µm diameter SMA nitinol wire with total stimulation of 180 ms, recovery time of 250 ms and contraction rate of 80/min.23 They achieved a maximum ejected volume of 330 mL/min, a generated systolic pressure of 75 mmHg, ejection fraction of 12% requiring a power supply of 6 V and 250 mA.23 This is comparable to our maximum ejected volume of 310 mL/min. In their experiments, a double-chamber setup was used, with balloon volume of only 50 mL. This is much smaller than patients with HFrEF22 making extrapolation of these results into a physiological situation difficult.
Diameter and Volume Displacement
Volume displacement and required voltage displayed a linear incremental relation in our experiment with the employed number of SMA-wires (windings) for all tested diameters (150, 250 and 380 µm), (Fig. 6a and b). This may suggest that the number of required SMA-wires for a specific volume displacement and the corresponding voltage may be predicted. An EF of 10% for this balloon (= 475 mL) would then require 46 windings, although maximum strain of SMAs might limit this linear behavior.
A lower pressure build up was observed in the first contraction cycles (Figs. 7a and 7b). Joule heating started the transformation phase but was not completed yet. After a few cycles temperature increased and the transformation phase was completed.11 A linear relationship between electric current increase and volume displacement was observed by Velazquez et al.24 Indeed, we observed that SMA wires had a higher volume displacement when increasing electric current (Fig. 8c). However, increasing electric currents above the plateau phase as observed in Fig. 8c, may cause overheating and induce stress fatigue. To reduce heating of surrounding tissue, a silicone tube proved to be effective in goat experiments.21 Indeed, Shiraishi et al. found no major draw backs related to heat production in silicone insulated SMA-wires in goats.21 Kalogerakos et al. found that insulated wires produced a lower volume displacement than non-insulated wires.12 Furthermore, cooling time is slower than heating time and thus urges for interval use such as once in four heart beats.
Pulse Width Modulation
Heart support during every heartbeat requires rapid compression and expansion of the SMA. This may not be directly attainable, though HF patients may already benefit from partial heart support. Hence the influence of pulse width modulation on volume displacement was investigated. SMA wires that were left to cool down before the following activation step produced substantially higher volume displacements (Fig. 9). In our experiment, pulse intervals of every 3 or every 5 cycles gave higher volume displacements than pulse intervals of every 1 or every 2 heart beats. A second, lower peak (“bounce”) was absent with a pulse interval of 1. Here, next activation occurred faster than cooldown and recovery of the SMA wire.
In this demonstrator study, hourly energy consumption of SMA activation ranged from 5.5 to 11.4 Watt-hour, where an increased energy use resulted in higher ejection fractions. This range is lower than the hourly energy consumption of 23.6 Watt-hour of a HeartMate II assist device25 and is comparable to SMA-prototypes12 or HeartMate III at 11 Watt–hour.18 At body temperature, SMA wires consume less energy than bench temperature due to a reduction in temperature gradient.10 This is promising for battery size reduction and therefore reduces frequent change of the (external) battery.
Limitations of Experimental Setup
A silicon pediatric resuscitation balloon was employed as a static model and acted as a mono-chamber model with a large end-diastolic volume (EDV) of 475 mL. EDV in HFrEF-patients range from 100 to 300 mL, depending on ventricular dilatation.22 Thus, this model underestimates effect size for clinical use.
Durability of SMAs for cardiac applications should extend beyond patients life expectancy. In this study, no change in volume displacement was observed after 25 min (Supplemental Fig. 1). Comparable SMAs were tested in a fatigue lifetime test and assured constant stroke after at least 106 cycles.7 However, for cardiac applications these experiments should ensure SMA stability over 108 cycles.
Also, afterload is reduced in LVAD therapy where effects of a SMA support device on afterload are still unknown. These effects should be addressed in future experimental setups and should be within physiological systemic aortal pressure.
Finally, energy consumption for achieving an ejection fraction of 3.5% was threefold higher than a pacemaker. This might affect future clinical use when battery life is too short for internal battery use. External battery use comes with an increased risk for driveline infections and impair patients mobility.16 An increase of parallel windings can reduce SMA length and resistance, with a reduction in energy consumption to follow.
Future research should focus on evaluation of spiral or oblique shaped configurations around the heart in advanced bench models such as dynamic setups or an ex vivo porcine cadaver model. The helical ventricular myocardial band cardiac fiber orientation should be acknowledged in these designs.13 This represents a physiologically more realistic model than the proof of principle in an in vitro mono-chamber bench model presented here. Alternatively, a double-chamber bench model with incorporated right ventricle can then include biventricular support. This should increase the technology readiness level from 3 (Characteristic Proof-of-Concept) to 4 (Proof-of-Concept in defined models). Furthermore, combining both different afterload scenarios such as hypertension or mitral regurgitation and design configurations in a mathematical model might enhance device development.
Effectivity of SMA-wire application may be objectified with (ex vivo) Magnetic Resonance Imaging (MRI) on segmental wall motion abnormalities. Also, a mesh such as the CorCap Cardiac Support Device or other supportive materials may be incorporated around the heart in future designs to guide and support SMA-wires and prevent dilatation of the left ventricle. This would also prevent incising heart tissue with SMA-wires. The resultant exoskeleton then prevents occurrence of dead space between SMA-wires and epicardium, thus giving additional support for effective contraction and improved ejection fraction.
An increased stroke volume of 11.8 mL improve patients New York Heart Association (NYHA) functional class on heart failure symptoms by a class.12 Our current setup might improve these symptoms by half a class, which is not clinically relevant yet. Future studies should aim to improve NYHA-class at least by one and preferably by two classes.
Optimal design characteristics of a SMA support device for HFrEF patients were determined in this demonstrator study. A LVEF increase of 3.5% was demonstrated in a mono-chamber static heart model by activation of SMA-wires. Furthermore, effects of configuration, duty cycle, frequency, pulse intervals and diameter on the activation of SMA-wires and corresponding volume displacement was evaluated.
The authors gratefully acknowledge funding by a Pioneers in Health Care 2017 (PIHC) Grant from the TechMed Centre, Enschede, the Netherlands.
Conflict of interest
Authors KA, FH, SS, JG, JP declare that they have no conflict of interest for this work. No human or animal studies were carried out by the authors for this article.
- 5.Dynalloy, I. Technical characteristics of Flexinol actuator wires. CA: Tustin, 2011.Google Scholar
- 8.Gerber, Y., S. A. Weston, M. M. Redfield, A. M. Chamberlain, S. M. Manemann, R. Jiang, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Inter. Med. 175(6):996–1004, 2015. https://doi.org/10.1001/jamainternmed.2015.0924.CrossRefGoogle Scholar
- 10.Ioannisa, H., L. Vlassioss, and P. D. Kalogerakos. Study of shape memory alloy fibers for the development of artificial myocardium. Hellenic J Cardiol. 51:301–309, 2010.Google Scholar
- 19.Ponikowski, P., A. A. Voors, S. D. Anker, H. Bueno, J. G. Cleland, A. J. Coats, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 37(27):2129–2200, 2016. https://doi.org/10.1093/eurheartj/ehw128.CrossRefGoogle Scholar
- 20.Sawyer, P., M. Page, L. Baseliust, C. McCool, E. Lester, B. Stanczewski, et al. Further study of nitinol wire as contractile artificial muscle for an artificial heart. Cardiovasc. Dis. 3(1):65, 1976.Google Scholar
- 21.Shiraishi, Y., Yambe, T., Saijo, Y., Sato, F., Tanaka, A., Yoshizawa, M., et al. (eds.). Morphological approach for the functional improvement of an artificial myocardial assist device using shape memory alloy fibres. Engineering in Medicine and Biology Society, 2007. EMBS 2007. 29th Annual International Conference of the IEEE, 2007Google Scholar
- 22.Solomon, S. D., E. Foster, M. Bourgoun, A. Shah, E. Viloria, M. W. Brown, et al. Effect of cardiac resynchronization therapy on reverse remodeling and relation to outcome: multicenter automatic defibrillator implantation trial: cardiac resynchronization therapy. Circulation 122(10):985–992, 2010. https://doi.org/10.1161/CIRCULATIONAHA.110.955039.CrossRefGoogle Scholar
- 23.Tozzi, P., A. Michalis, D. Hayoz, D. Locca, and L. K. von Segesser. Artificial muscle for end-stage heart failure. ASAIO J. 58(2):103–108, 2012.Google Scholar
- 24.Velazquez, R., and E. E. Pissaloux. Modelling and temperature control of shape memory alloys with fast electrical heating Int J Mech. Control 13(02):3–10, 2012.Google Scholar
- 26.WHO. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: WHO, 1992.Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.